Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
06/2012
06/21/2012WO2012027555A3 Glycated cd59 peptides, their preparation, and uses thereof
06/21/2012WO2012022982A3 Improved antibodies of the class igg4
06/21/2012WO2012021512A3 Erythrocyte-binding therapeutics
06/21/2012WO2009145810A3 St2-based dengue fever diagnostic
06/21/2012US20120159661 T-Bet Compositions and Methods of Use Thereof
06/21/2012US20120159658 Extracellular vesicles derived from gram-positive bacteria, and use thereof
06/21/2012US20120156725 Human Anti-OPGL Neutralizing Antibodies As Selective OPGL Pathway Inhibitors
06/21/2012US20120156649 Methods for treating dental diseases, disorders, and injuries
06/21/2012US20120156287 Use of Vitelline Protein B as a Microencapsulating Additive
06/21/2012US20120156284 Enhanced biological autologous tissue adhesive composition and methods of preparation and use
06/21/2012US20120156283 Methods and Compositions for Wound Treatment
06/21/2012US20120156282 Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails
06/21/2012US20120156281 Meningococcal Vaccine Based on Lipooligosaccharide (LOS) and Neisseria Meningitidis Protein
06/21/2012US20120156280 Myeloid derived suppressor cell inhibiting agents
06/21/2012US20120156265 Conformable tissue repair implant capable of injection delivery
06/21/2012US20120156258 Adjuvant or pharmaceutical preparation for transdermal or transmucosal administration
06/21/2012US20120156251 Cationic oil-in-water emulsions
06/21/2012US20120156248 Augmentation of titer for vaccination in animals
06/21/2012US20120156246 Reprogramming cancer cells
06/21/2012US20120156245 Methods for the Prevention of Malaria
06/21/2012US20120156244 Nasal Compositions and Uses Thereof
06/21/2012US20120156243 Norovirus vaccine formulations
06/21/2012US20120156242 An Antigenic Peptide Derived From Influenza Virus And A Method For Selecting Anti-Influenza Virus Antibody
06/21/2012US20120156241 Rescue of influenza virus
06/21/2012US20120156240 Methods for preparing vesicles and formulations produced therefrom
06/21/2012US20120156239 Optimized vaccines to provide protection against ebola and other viruses
06/21/2012US20120156238 Herpes virus backbone for viral vaccine and vaccine based thereon
06/21/2012US20120156237 Novel Antitoxin and Vaccine Platform Based on Nodavirus VLPS
06/21/2012US20120156236 Neisseria meningitidis antigens and compositions
06/21/2012US20120156235 Antibodies Against And Methods For Producing Vaccines For Respiratory Syncytial Virus
06/21/2012US20120156234 Means for treating synucleinopathies
06/21/2012US20120156233 Vaccine therapy for choroidal neovascularization
06/21/2012US20120156232 Cancer vaccines and vaccination methods
06/21/2012US20120156231 Foxm1 peptides and vaccines containing the same
06/21/2012US20120156230 Treatment of spinal cord injury and traumatic brain injury using placental stem cells
06/21/2012US20120156229 Quickly soluble oral film dosage containing steviosides as a unpleasant taste masking agent
06/21/2012US20120156228 Methods, Kits, and Compositions for Generating New Hair Follicles and Growing Hair
06/21/2012US20120156227 Proteins modified with (amino) monosaccharide-biotin adduct
06/21/2012US20120156226 Marker Differentially Expressed in Cancer Stem Cells and Methods of Using Same
06/21/2012US20120156225 Method of therapy
06/21/2012US20120156224 Modulation of tim receptor activity in combination with cytoreductive therapy
06/21/2012US20120156223 Method for Inhibiting Scavenger Receptor-A and Increasing Immune Response to Antigens
06/21/2012US20120156222 Prevention and treatment of alzheimer's disease
06/21/2012US20120156221 Method and Pharmaceutical Composition for Use in the Treatment of Neurodegenerative Disorders
06/21/2012US20120156220 Methods and compositions for inhibiting cd32b expressing cells
06/21/2012US20120156219 Nitrogen-containing heterocyclic compounds and medicinal use thereof
06/21/2012US20120156218 Novel anti-cd38 antibodies for the treatment of cancer
06/21/2012US20120156217 Novel EGFR-Binding Molecules and Immunoconjugates Thereof
06/21/2012US20120156216 Methods and Compositions for Treatment of Tumor Metastasis
06/21/2012US20120156215 Phage-GnRH Constructs, Their Mimics, Antigenic Compositions, and Sequences for Immunocontraception of Animals and Other Applications
06/21/2012US20120156214 Soluble lymphotoxin-beta receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological diseases
06/21/2012US20120156213 Method for treating th17 inflammatory disease through inhibition of vascular endothelial growth factor receptors and pharmaceutical composition therefor
06/21/2012US20120156212 Methods and compositions for treating neoplasia
06/21/2012US20120156211 Porphyromonas gingivalis polypeptides
06/21/2012US20120156210 Methods of treatment using anti-il-22ra antibodies
06/21/2012US20120156209 Anti-il-tif antibodies and methods of use
06/21/2012US20120156208 Therapeutic uses of inhibitors of rtp801
06/21/2012US20120156207 Methods and compositions for inhibiting cd32b expressing cells
06/21/2012US20120156206 C-met antibody combinations
06/21/2012US20120156205 Monoclonal antibodies to progastrin
06/21/2012US20120156204 Methods for increasing adiponectin
06/21/2012US20120156203 Novel anti-il13 antibodies and uses thereof
06/21/2012US20120156202 Age related macular degeneration treatment
06/21/2012US20120156201 Humanized antibodies specific for hsp65-derived peptide-6 methods and uses thereof
06/21/2012US20120156200 Method of treating cancer
06/21/2012US20120156199 Use of picoplatin to treat colorectal cancer
06/21/2012US20120156198 Antibodies against IL-18R1 and uses thereof
06/21/2012US20120156197 Combination therapy with mdm2 and efgr inhibitors
06/21/2012US20120156196 Anti-anthrax antibody, formulations thereof, and methods of use
06/21/2012US20120156195 Human-Murine Chimeric Antibodies Against Respiratory Syncytial Virus
06/21/2012US20120156194 Diagnosis and treatments relating to th2 inhibition
06/21/2012US20120156193 Antibodies That Specifically Bind to A Beta Oligomers and Use Thereof
06/21/2012US20120156192 Treatment of Diseases and Disorders Using Self-Renewing Colony Forming Cells Cultured and Expanded In Vitro
06/21/2012US20120156191 Anti-jam-a antibodies
06/21/2012US20120156164 In situ-forming hydrogel for tissue adhesives and biomedical use thereof
06/21/2012US20120156134 Compositions and methods for detecting or eliminating senescent cells to diagnose or treat disease
06/21/2012US20120156131 Diagnosis and treatment of tumors
06/21/2012US20120156130 Use of her3 binding agents in prostate treatment
06/21/2012US20120156129 Novel antibodies
06/21/2012CA2821582A1 Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
06/21/2012CA2821492A1 Vaccine antigens that direct immunity to conserved epitopes
06/21/2012CA2821296A1 Cd89 activation in therapy
06/21/2012CA2821289A1 Adenovirus serotype 26 and serotype 35 filovirus vaccines
06/21/2012CA2821268A1 Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
06/21/2012CA2821141A1 Nanoparticles comprising at least one active agent and at least two polyelectrolytes
06/21/2012CA2821138A1 Process for preparing nanoparticles of two polyamino acids of opposite charge, one of the two of which is in charge surplus
06/21/2012CA2821080A1 Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer
06/21/2012CA2820924A1 Method for suppressing an immune response
06/21/2012CA2819298A1 Mycobacterium antigenic composition
06/21/2012CA2819297A1 Mycobacterium antigenic composition
06/21/2012CA2817380A1 Diagnosis and treatments relating to th2 inhibition
06/21/2012CA2787598A1 Irradiated biodegradable polymer microparticles
06/20/2012EP2465928A1 Treatment of Th17-mediated diseases
06/20/2012EP2465927A1 Influenza hemagglutinin and neuraminidase variants
06/20/2012EP2465867A2 Peptide vaccines for cancers expressing tumor-associated antigens
06/20/2012EP2465866A2 Peptide vaccines for cancers expressing tumor-associated antigens
06/20/2012EP2465865A2 Peptide vaccines for cancers expressing tumor-associated antigens
06/20/2012EP2465864A2 Peptide vaccines for cancers expressing tumor-associated antigens
06/20/2012EP2465538A2 Use of immunesuppressant receptor
06/20/2012EP2465536A1 CD89 activation in therapy
1 ... 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 ... 1823